Joinn

During the Covid pandemic, lab monkeys that are one of Joinn’s main businesses were in short supply as companies rushed to develop Covid vaccines and drugs.

FAST NEWS: Joinn Lab swings to the red on falling revenue

The Latest: Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), said on Wednesday it expects to report a net loss of 136 million yuan ($18.7…
6127.HK 603127.SHG

Recent Articles

RELATED ARTICLES

  1. Everest Medicines eyes cash break even
    Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  2. Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  3. Cancer drug maker Genfleet joins Hong Kong IPO influx
  4. As Covid drug cash dwindles, Vigonvita targets new remedies
  5. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  6. Cancer drug maker Biostar shines on Hong Kong market debut
    2563.HK
  7. Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva